LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MCF7 | Seliciclib | 0.37 | uM | LJP5 | 3 | J04 | 72 | hr | 1235 | 3984 | 4156 | 0.9586 | 0.9411 |
MCF7 | Ruxolitinib | 0.37 | uM | LJP5 | 1 | O16 | 72 | hr | 1235 | 3642 | 4156 | 0.8763 | 0.8240 |
MCF7 | Ruxolitinib | 0.37 | uM | LJP5 | 2 | O16 | 72 | hr | 1235 | 3897 | 4156 | 0.9376 | 0.9113 |
MCF7 | Ruxolitinib | 0.37 | uM | LJP5 | 3 | O16 | 72 | hr | 1235 | 4382 | 4156 | 1.0543 | 1.0773 |
MCF7 | XL147 | 0.37 | uM | LJP5 | 1 | G10 | 72 | hr | 1235 | 4602 | 4156 | 1.1073 | 1.1526 |
MCF7 | XL147 | 0.37 | uM | LJP5 | 2 | G10 | 72 | hr | 1235 | 4472 | 4156 | 1.0760 | 1.1081 |
MCF7 | XL147 | 0.37 | uM | LJP5 | 3 | G10 | 72 | hr | 1235 | 4553 | 4156 | 1.0955 | 1.1359 |
MCF7 | Saracatinib | 0.37 | uM | LJP6 | 1 | D10 | 72 | hr | 1235 | 2209 | 4156 | 0.5315 | 0.3333 |
MCF7 | Saracatinib | 0.37 | uM | LJP6 | 2 | D10 | 72 | hr | 1235 | 1885 | 4156 | 0.4535 | 0.2224 |
MCF7 | Saracatinib | 0.37 | uM | LJP6 | 3 | D10 | 72 | hr | 1235 | 1947 | 4156 | 0.4685 | 0.2436 |
MCF7 | Selumetinib | 0.37 | uM | LJP6 | 1 | M10 | 72 | hr | 1235 | 3181 | 4156 | 0.7654 | 0.6661 |
MCF7 | Selumetinib | 0.37 | uM | LJP6 | 2 | M10 | 72 | hr | 1235 | 2543 | 4156 | 0.6119 | 0.4477 |
MCF7 | Selumetinib | 0.37 | uM | LJP6 | 3 | M10 | 72 | hr | 1235 | 2913 | 4156 | 0.7009 | 0.5744 |
MCF7 | Sirolimus | 0.37 | uM | LJP6 | 1 | L16 | 72 | hr | 1235 | 2543 | 4156 | 0.6119 | 0.4477 |
MCF7 | Sirolimus | 0.37 | uM | LJP6 | 2 | L16 | 72 | hr | 1235 | 2222 | 4156 | 0.5346 | 0.3378 |
MCF7 | Sirolimus | 0.37 | uM | LJP6 | 3 | L16 | 72 | hr | 1235 | 2732 | 4156 | 0.6573 | 0.5124 |
MCF7 | Sorafenib | 0.37 | uM | LJP6 | 1 | B10 | 72 | hr | 1235 | 3940 | 4156 | 0.9480 | 0.9260 |
MCF7 | Sorafenib | 0.37 | uM | LJP6 | 2 | B10 | 72 | hr | 1235 | 4099 | 4156 | 0.9863 | 0.9804 |
MCF7 | Sorafenib | 0.37 | uM | LJP6 | 3 | B10 | 72 | hr | 1235 | 3685 | 4156 | 0.8866 | 0.8387 |
MCF7 | SU11274 | 0.37 | uM | LJP5 | 1 | J10 | 72 | hr | 1235 | 4510 | 4156 | 1.0851 | 1.1211 |
MCF7 | SU11274 | 0.37 | uM | LJP5 | 2 | J10 | 72 | hr | 1235 | 4606 | 4156 | 1.1082 | 1.1540 |
MCF7 | SU11274 | 0.37 | uM | LJP5 | 3 | J10 | 72 | hr | 1235 | 4675 | 4156 | 1.1248 | 1.1776 |
MCF7 | Fedratinib | 0.37 | uM | LJP5 | 1 | L04 | 72 | hr | 1235 | 3580 | 4156 | 0.8614 | 0.8027 |
MCF7 | Fedratinib | 0.37 | uM | LJP5 | 2 | L04 | 72 | hr | 1235 | 3836 | 4156 | 0.9230 | 0.8904 |
MCF7 | Fedratinib | 0.37 | uM | LJP5 | 3 | L04 | 72 | hr | 1235 | 3122 | 4156 | 0.7512 | 0.6459 |